Commentary

Video

Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCC

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard, discusses findings from a phase 2 trial (NCT03526835) evaluating frontline petosemtamab (MCLA-158) plus pembrolizumab (Keytruda) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

This trial assessed the combination of petosemtamab and pembrolizumab in 24 efficacy-evaluable patients with previously untreated, recurrent or metastatic PD-L1–positive HNSCC with an ECOG performance status of 0 or 1 and measurable disease. The combination elicited an overall response rate (ORR) of 67% (95% CI, 45%-84%), including 1 complete response (CR), 12 partial responses (PRs), and 3 unconfirmed PRs. This ORR is numerically higher than the ORRs seen with TKIs and cetuximab (Erbitux) in this patient population, Fayette notes.

Response rates were similar between the HPV-positive and HPV-negative patient populations, as well as between the PD-L1–high and PD-L1–low populations, Fayette explains. In total, 42% of patients had a PD-L1 combined positive score (CPS) of 1 to 19, and 56% of patients had a PD-L1 CPS of 20 or higher. Among patients with low PD-L1 CPS, the ORR was 60%, with best responses of PD (n = 2), SD (n = 2), unconfirmed PR (n = 1), PR (n = 4), and CR (n = 1). In patients with high PD-L1 CPS, the ORR was 71%, with best responses of PD (n = 1), SD (n = 3), unconfirmed PR (n = 2), and PR (n = 8). Among patients with (57%) and without HPV type 16 (36%), the respective ORRs were 75% and 65%. Investigators observed no correlation between ORR and OS outcomes, Fayette notes.

Although longer follow-up data from this phase 2 trial are necessary to confirm the benefit of petosemtamab plus pembrolizumab in this patient population, current findings supported the initiation of a phase 3 registrational trial evaluating the combination vs pembrolizumab alone in the frontline setting, Fayette emphasizes. This trial is expected to begin at the end of 2024, Fayette concludes.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC